For young children in Africa who return home after hospitalization for severe anemia, monthly long-acting malaria prophylaxis can reduce the rates of readmission and death during the three months following hospitalization.
In a retrospective study of American military women involving 50 treated with atovaquone-proguanil and 156 exposed to mefloquine, no increase in risk of fetal loss or adverse infant outcomes was identified. Atovaquone-proguanil seems safe for use in pregnancy, but data are limited.
A non-pathogenic microsporidian organism can infect Anopheles mosquitoes and block the transmission of malaria parasites, without negatively altering the life of the mosquito. This organism potentially could be used for widespread malaria control.
In a retrospective study of American military women involving 50 treated with atovaquone-proguanil and 156 exposed to mefloquine, no increase in risk of fetal loss or adverse infant outcomes was identified. Atovaquone-proguanil seems safe for use in pregnancy, but data are limited.
There is a statistical association between a urine test suggestive of exposure to pyrethroid insecticides and increased mortality over the subsequent 14 years.
There is a statistical association between having a urine test suggestive of exposure to pyrethroid insecticides and increased mortality over the subsequent 14 years.
Tafenoquine is effective for the prevention of all species of malaria and can be used to prevent relapse of Plasmodium vivax and Plasmodium ovale. G6PD status should be evaluated prior to use.
Transplacental antibodies against Plasmodium falciparum Schizont Egress Antigen-1 may protect infants from severe malarial infection during the first year of life. This new knowledge about these antibodies potentially can inform vaccine development.
